Ironwood Pharmaceuticals (IRWD) Long-Term Deferred Tax (2021 - 2026)

Ironwood Pharmaceuticals has disclosed Long-Term Deferred Tax across 6 years of filings, most recently posting $69.1 million for Q2 2026.

• In Q2 2026, Long-Term Deferred Tax fell 46.65% year-over-year to $69.1 million; the TTM figure through Jun 2026 stood at $69.1 million (down 46.65% YoY), while the FY2025 annual figure was $103.4 million, down 28.29% from the prior year.
• Long-Term Deferred Tax came in at $69.1 million for Q2 2026 at Ironwood Pharmaceuticals, down from $84.2 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $335.4 million in Q1 2022 to a low of $69.1 million in Q2 2026.
• Average Long-Term Deferred Tax over 5 years is $199.2 million, with a median of $199.6 million recorded in 2024.
• Year-over-year, Long-Term Deferred Tax dropped 5.11% in 2022 and tumbled 46.65% in 2026.
• Over 5 years, Long-Term Deferred Tax stood at $283.7 million in 2022, then dropped by 25.15% to $212.3 million in 2023, then sank by 32.07% to $144.2 million in 2024, then dropped by 28.29% to $103.4 million in 2025, then slumped by 33.23% to $69.1 million in 2026.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $69.1 million in Q2 2026, $84.2 million in Q1 2026, and $103.4 million in Q4 2025.